

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Zhi <i>et al.</i>	Art Unit	: 1625
Serial No.	: 10/684,212	Examiner	: Aulakh, Charanjit
Filed	: October 10, 2003	Conf. No.	: 8674
Cust. No.	: 13565		
Title	: 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-F]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS		

POWER OF ATTORNEY BY ASSIGNEE

Dear Sir:

As the below-named assignee of the above-identified application ("Application"), LIGAND PHARMACEUTICALS INCORPORATED, through its duly-delegated representative, hereby revokes all previous powers of attorney given in the above-identified application and appoints the following as its attorneys, with full power of substitution and revocation, to prosecute the Application and to transact all business in the United States Patent and Trademark Office connected therewith:

STEPHANIE SEIDMAN, Registration No. 33,779
FRANK J. MISKIEL, Registration No. 53,332
KAREN G. POTTER, Registration No. 57,254; and
The ATTORNEYS of U.S. CUSTOMER NO. 13565.

STATEMENT UNDER 37 C.F.R. 3.73(b):

LIGAND PHARMACEUTICALS INCORPORATED is the assignee of the entire right, title and interest in the above-identified application by virtue of a chain of title from the inventors of the application listed above and its priority applications/patents, to the current assignee as follows:

Assignment from Lin Zhi; Cornelis Arjan Van Oeveren; Bijan Pedram; and Donald S. Karanewsky to LIGAND PHARMACEUTICALS INCORPORATED, recorded in the United States Patent and Trademark Office on Reel 015455, Frame 0895 for U.S. Serial Number 10/684,212.

Applicant: : Zhi *et al.*
Serial No. : 10/684,212
Filed : October 10, 2003

Attorney Docket No.: 33310.01087.US01/1087
Power of Attorney

Direct all Correspondence to: **USPTO CUSTOMER NO. 13565**


McKENNA LONG & ALDRIDGE, LLP
4435 Eastgate Mall, Suite 400
San Diego, California 92121

Direct all telephonic inquiries to:

Stephanie Seidman, Registration No. 33,779
Telephone: 619-595-8010

The undersigned is authorized to act on behalf of the assignee:

LIGAND PHARMACEUTICALS INCORPORATED

By: 
(Signature)

Name: Charles S. Berkman
(Typed or Printed Name)

Title: Vice President, General Counsel & Secretary

Date: May 31, 2011

SD:22235075:1